Capitalizing on healthcare innovation through flexible financing solutions

The healthcare sector, despite being favored by analysts and fund managers as a promising market segment, has encountered headwinds at the beginning of 2024.^[1] While the S&P 500 healthcare sector (.SPXHC) has demonstrated a surge of approximately 6% since December, its overall performance in 2023 showed only a modest increase of 0.3% compared to the broader index’s notable 24% jump.^[2] Paradoxically, this lackluster performance has presented an attractive opportunity for investors seeking undervalued market segments.

Analysts at JPMorgan point out that certain areas within the sector, such as large-cap drugmakers and biotech firms, show significant discounts, with some trading at a “historically low” level of 30% below the S&P 500^[3]. This makes them appealing to investors seeking to diversify their portfolios. In the face of a challenging fundraising environment, progressive capital solutions like securities-backed financing from EquitiesFirst are playing a pivotal role in supporting healthcare transactions and investments.

Investment opportunities in a post-pandemic healthcare landscape

Research conducted by Bain & Company reveals that the healthcare industry is currently experiencing a significant boost in health investing. This momentum can be attributed to the wave of innovation triggered by the COVID-19 pandemic.^[4] The global healthcare landscape has witnessed a remarkable transformation as healthcare providers and organizations rapidly adopt digital solutions and advanced technologies to address the challenges posed by the pandemic.

As we approach the four-year mark since the onset of the pandemic, healthcare leaders are facing heightened expectations to deliver results. However, they are also grappling with persistent challenges such as margin pressures and workforce shortages.^[5] In response, the healthcare industry is increasingly prioritizing strategic initiatives aimed at enhancing patient experiences and improving healthcare outcomes. This includes leveraging technological advancements such as artificial intelligence (AI), which also promises to drive significant productivity gains and create opportunities for investors.^[6]

In the unfolding landscape of 2024, a persistent disinflationary trend is anticipated across Europe and North America, prompting policymakers to embark on rate-cutting measures. According to Invesco’s projections, the technology sector emerges with a positive outlook, poised for enhanced earnings amid declining rates.^[7] This optimistic scenario catalyzes increased economic activities and heightens investment appetite, underlining the importance of flexible financing solutions to facilitate sustained growth throughout the year.

Securities-backed financing drives growth and transformation in healthcare

In the dynamic landscape of the healthcare sector, where investors are actively exploring high-reward opportunities, the need for reliable liquidity solutions remains constant. Considering these macroeconomic factors, funding solutions such as securities-backed financing offered by EquitiesFirst can prove to be valuable tools. This innovative funding solution helps long-term investors access relatively stable and cost-effective capital by extracting value from their securities or digital assets. Such flexibility can enable investors to make equity investments in emerging healthcare themes or technologies, playing a crucial role in driving the development and commercialization of cutting-edge healthcare solutions and fostering transformative growth within the sector.

EquitiesFirst’s non-recourse, non-purpose capital can allow investors to seize opportunities and deploy their investment strategies according to their own discretion in the healthcare sector, a domain marked by innovation and burgeoning growth potential. As the healthcare industry continues its transformative journey, this strategic financing tool enhances investment flexibility and resilience. By affording investors the latitude to seize opportunities and tailor their strategies in alignment with the sector’s continuous evolution, EquitiesFirst positions itself as a responsive partner in the pursuit of strategic investment goals.

[1] https://www.nasdaq.com/articles/healthcare-investing-in-2024

[2] https://www.spglobal.com/spdji/en/indices/equity/sp-500-health-care-sector/#overview

[3] https://www.reuters.com/business/healthcare-pharmaceuticals/unloved-healthcare-stocks-draw-investors-despite-us-election-risks-2024-01-08/

[4] https://www.bain.com/globalassets/noindex/2024/bain_report_global_healthcare_private_equity_2024.pdf

[5] https://www.jpmorgan.com/insights/banking/commercial-banking/healthcare-advisory-council-hcac

[6] https://www.healthcaredive.com/spons/the-next-era-of-hospital-healthtech-and-outsourced-provider-partnerships/701087/

[7] https://www.invesco.com/apac/en/institutional/insights/market-outlook/investment-outlook.html

Disclaimer

Past performance does not guarantee future returns, and individual returns are not guaranteed or warranted.

This Document is intended solely for accredited investors, sophisticated investors, professional investors, or otherwise qualified investors, as may be required by law or otherwise, and it is not intended for, and should not be used by, persons who do not meet the relevant requirements. The content provided herein is for informational purposes only and is general in nature and not targeted to any specific objective or financial need. The views and opinions expressed in this Document have been prepared by third parties and do not necessarily reflect the views and opinions of EquitiesFirst. EquitiesFirst has not independently examined or verified the information provided herein, and no representation is made that it is accurate or complete. Opinions and information herein are subject to change without notice. The content provided does not constitute an offer to sell (or solicitation of an offer to purchase) any securities, investments, or any financial products (“Offer”). Any such Offer shall only be made through a relevant offering or other documentation which sets forth its material terms and conditions. Nothing contained in this Document shall constitute a recommendation, solicitation, invitation, inducement, promotion, or offer for the purchase or sale of any investment product by Equities First Holdings, LLC or its subsidiaries (collectively, “EquitiesFirst”), nor shall this Document be construed in any way as investment, legal, or tax advice, or as a recommendation, reference, or endorsement by EquitiesFirst. You should seek independent financial advice prior to making an investment decision about a financial product.

This Document contains the intellectual property of EquitiesFirst in the United States and other countries, including, without limitation, their respective logos and other registered and unregistered trademarks and service marks. EquitiesFirst reserves all rights in and to their intellectual property contained in this Document. The Document should not be distributed, published, reproduced or otherwise made available in whole or in part by recipients to any other person and, in particular, should not be distributed to persons in any country where such distribution may lead to a breach of any legal or regulatory requirement.

EquitiesFirst make no representation or warranty with respect to this Document and expressly disclaim any implied warranty under law. You acknowledge that EquitiesFirst is not liable under any circumstances for any direct, indirect, special, consequential, incidental, or punitive damages whatsoever, including, without limitation, any lost profits or lost opportunity, even if EquitiesFirst has been advised of the possibility of such damages.

EquitiesFirst makes the following further statements that may be applicable in the stated jurisdiction:

The information contained on this Document is intended for persons located in Australia only and classified as a Wholesale Client only as defined in Section 761G of the Corporations Act 2001. The distribution of information to persons outside this criteria may be restricted by law and persons who come into possession of it should seek advice and observe any such restriction.

The material contained in this Document is for information purposes only and should not be construed as an offer or solicitation or recommendation to buy or sell financial products.

The information contained in this Document is intended to be general in nature and is not personal financial product advice. Any advice contained in the Document is general advice only and has been prepared without considering your objectives, financial situation or needs. Before acting on any information, you should consider the appropriateness of the information provided and the nature of the relevant financial product having regard to your objectives, financial situation and needs. You should seek independent financial advice and read the relevant disclosure statements or other offer documents prior to making an investment decision about a financial product.

Dubai: Equities First Holdings Hong Kong Ltd (DIFC Representative Office) at Gate Precinct Building 4, 6th Floor, Office 7, Dubai International Financial Centre (commercial license number CL7354) is regulated by the Dubai Financial Services Authority (“DFSA”) as a Representative Office (DFSA Firm Reference No.: F008752). All rights reserved.

The information contained in this document is intended to be general in nature, and, to the extent that it is perceived as advice, any advice contained in this document is general advice only and has been prepared without considering your objectives, financial situation, suitability of the financial products or your needs.

The material contained in this document is for information purposes only and should not be construed as financial advice, including an offer or solicitation or recommendation to buy or sell financial products. The information contained in this document is intended to be general in nature and any advice contained in this document is general advice only and has been prepared without considering your objectives, financial situation, suitability of the financial products or your needs. Before acting on any information, you should consider the appropriateness of the information provided and the nature of the relevant financial product having regard to your objectives, financial situation and needs. If you do not understand the contents of this document, you should consult an authorised financial adviser.

This document relates to a financial product which is not subject to any form of regulation or approval by the DFSA. The DFSA has no responsibility for reviewing or verifying any documents in connection with this financial product. Accordingly, the DFSA has not approved this document or any other associated documents nor taken any steps to verify the information set out in this document, and has no responsibility for it.

Hong Kong: Equities First Holdings Hong Kong Limited is licensed under the Money Lenders Ordinance (Money Lender’s Licence No. 1659/2024) and to carry on the business of dealing in securities (Type 1 licence) under the Securities and Futures Ordinance (“SFO”) (CE No. BFJ407). This Document has not been reviewed by the Hong Kong Securities and Futures Commission. It is not intended as an offer to sell securities or a solicitation to buy any product managed or provided by Equities First Holdings Hong Kong Limited and is only intended for persons who qualify as Professional Investors under the SFO. This document is not directed to individuals or organizations for whom such offers or invitations would be unlawful or prohibited.

Korea: The foregoing is intended solely for sophisticated investors, professional investors or otherwise qualified investors who have sufficient knowledge and experience in entering into securities financing transactions. It is not intended for, and should not be used by, persons who do not meet those criteria.

United Kingdom: Equities First (London) Limited is authorised and regulated in the UK by the Financial Conduct Authority (“FCA”). In the UK, this Document is only being distributed and made available to persons of the kind described in Article 19(5) (investment professionals) and Article 49(2) (high net worth companies, unincorporated associations etc.) of Part IV of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (‘’FPO’’) and any investment activity to which this presentation relates is only available to, and will only be engaged in with, such persons. Persons who do not have professional experience in matters relating to investment or who are not persons to whom Article 49 of the FPO applies should not rely on this document. This Document is only prepared for and available to persons who qualify as Professional Investors under the Markets in Financial Instruments Directive.